BACKGROUND: Thrombophilic mutations in genes for factor V Leiden and factor II prothrombin are among the most important risk factors for developing the thromboembolic disease (TED), along with the use of oral contraceptives (OCs) or smoking. AIM: This study aimed to investigate the occurrence of risk factors in young women using droplet digital PCR (ddPCR) and, based on the results of this investigation, to perform a cost-benefit analysis of ddPCR-based screening in young women starting to take OCs compared to the treatment costs of patients who develop preventable TED in the Czech Republic. METHODS: In this cross-sectional study, female university students filled in a questionnaire and provided a blood sample for DNA isolation and ddPCR analysis of both aforementioned genetic risk factors. The results, along with data from literature and web search, were used for cost-benefit analysis valid for the Czech Republic. RESULTS: Out of 148 participants, 30 (20%) were smokers and 49 (33%) took OCs. A mutation was confirmed in 6 women (4.1%) in the factor V gene and in 3 women (2%) in the factor II gene, respectively. A model calculation on a cohort of 50,000 women starting to use contraceptives in the Czech Republic every year showed that at maximum compliance, (i.e., non-use of OC and smoking cessation), screening could prevent 68 cases of TED over the course of the mean period of OC use (5.7 years). Economically, the costs of testing in this cohort (2.25 mil. USD) would be significantly lower than prevented treatment costs (16 mil. USD at maximum compliance); the cost-benefit break-even point would be at 14.1% compliance. CONCLUSION: The cost-benefit analysis based on our results indicates that screening for factor V Leiden and factor II prothrombin in young women before starting to use OCs would, in the conditions of the Czech Republic, likely be highly economically effective.

Centre for Epidemiological Research Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Department of Epidemiology and Public Health Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Zobrazit více v PubMed

ICD-10. [(accessed on 30 September 2021)]. Available online: https://icd.who.int/browse10/2010/en#/I74.9arising.

Khan S., Dickerman J.D. Hereditary Thrombophilia. Thromb. J. 2006;4:15. doi: 10.1186/1477-9560-4-15. PubMed DOI PMC

Kujovich J.L. Factor v Leiden Thrombophilia. Genet. Med. 2011;13:1–16. doi: 10.1097/GIM.0b013e3181faa0f2. PubMed DOI

Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D.O., Walker I.D., Greaves M., Brenkel I., Regan L., et al. Thrombophilia in Pregnancy: A Systematic Review. Br. J. Haematol. 2006;132:171–196. doi: 10.1111/j.1365-2141.2005.05847.x. PubMed DOI

Simcox L.E., Ormesher L., Tower C., Greer I.A. Thrombophilia and Pregnancy Complications. Int. J. Mol. Sci. 2015;16:28418–28428. doi: 10.3390/ijms161226104. PubMed DOI PMC

Ionita I., Grigorita L., Miloicov C.B., Petre I., Bernad E., Craina M., Diaconu M., Citu C., Radu F., Oros D., et al. The Role of Thrombophilia in Pregnancy. Rev. Chim. 2016;67:2643–2647. doi: 10.1155/2013/516420. DOI

Patel K., Fasanya A., Yadam S., Joshi A.A., Singh A.C., DuMont T. Pathogenesis and Epidemiology of Venous Thromboembolic Disease. Crit. Care Nurs. Q. 2017;40:191–200. doi: 10.1097/CNQ.0000000000000158. PubMed DOI

Campello E., Spiezia L., Simioni P. Diagnosis and Management of Factor V Leiden. Expert Rev. Hematol. 2016;9:1139–1149. doi: 10.1080/17474086.2016.1249364. PubMed DOI

Jak se Pripravek Lindynette 20 uziva. [(accessed on 21 September 2021)]. Available online: https://farmaceutika.info/lindynette-20.

Simone B., De Stefano V., Leoncini E., Zacho J., Martinelli I., Emmerich J., Rossi E., Folsom A.R., Almawi W.Y., Scarabin P.Y., et al. Risk of Venous Thromboembolism Associated with Single and Combined Effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate Reductase C677T: A Meta-Analysis Involving over 11,000 Cases and 21,000 Controls. Eur. J. Epidemiol. 2013;28:621–647. doi: 10.1007/s10654-013-9825-8. PubMed DOI PMC

Dziadosz M., Baxi L.V. Global Prevalence of Prothrombin Gene Mutation G20210A and Implications in Women’s Health a Systematic Review. Blood Coagul. Fibrinolysis. 2016;27:481–489. doi: 10.1097/MBC.0000000000000562. PubMed DOI

Dulicek M.P., Kalousek M.I., Maly J. Hormonální antikoncepce a tromboembolická nemoc–jak je to ve skutečnosti. Interni Med. 2002;4:6–9.

Gennet. [(accessed on 7 August 2021)]. Available online: https://www.gennet.cz/trombofilni-mutace.

Gomes M.P.V., Deitcher S.R. Risk of Venous Thromboembolic Disease Associated with Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review. Arch. Intern. Med. 2004;164:1965–1976. doi: 10.1001/archinte.164.18.1965. PubMed DOI

Dulicek P., Ivanova E., Kostal M., Sadilek P., Beranek M., Zak P., Hirmerova J. Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use. Clin. Appl. Thromb. 2018;24:797–802. doi: 10.1177/1076029617727857. PubMed DOI PMC

Van Vlijmen E.F.W., Veeger N.J.G.M., Middeldorp S., Hamulyák K., Prins M.H., Büller H.R., Meijer K. Thrombotic Risk during Oral Contraceptive Use and Pregnancy in Women with Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception. Blood. 2011;118:2055–2061. doi: 10.1182/blood-2011-03-345678. PubMed DOI

Hotoleanu C. Genetic Risk Factors in Venous Thromboembolism Controls. Thromb. Embolism Res. Clin. Pract. 2016;906:253–272. PubMed

Havlín M.M. Riziko Tromboembolické Nemoci Mladistvých Uživatelek Hormonální Antikoncepce. Pediatrie Pro Praxi. 2017;18:348–351. doi: 10.36290/ped.2017.067. PubMed DOI

Biorad . Droplet Digital TM PCR Applications Guide. Biorad; Hercules, CA, USA: 2018. 145p

Masarykův Onkologický Ústav. [(accessed on 2 September 2021)]. Available online: https://static.mou.cz/d/mou.cz/files/4325.pdf/s-7d32577f291a?_ts=1622476O83.

Genetika KV. [(accessed on 2 September 2021)]. Available online: http://www.genetikakv.cz/dokumenty/cenik.pdf.

Pomp E.R., Rosendaal F.R., Doggen C.J.M. Smoking Increases the Risk of Venous Thrombosis and Acts Synergistically with Oral Contraceptive Use. Am. J. Hematol. 2008;83:97–102. doi: 10.1002/ajh.21059. PubMed DOI

Enga K.F., Brækkan S.K., Hansen-Krone I.J., Le Cessie S., Rosendaal F.R., Hansen J.B. Cigarette Smoking and the Risk of Venous Thromboembolism: The Tromsø Study. J. Thromb. Haemost. 2012;10:2068–2074. doi: 10.1111/j.1538-7836.2012.04880.x. PubMed DOI

EUC Laboratoře. [(accessed on 2 September 2021)]. Available online: https://www.euclaboratore.cz/-a4010?field=data.

Hnilickova I. Leidenská Mutace. Bakalářská Práce- Fakulta Chemicko- Technologická. 2017. [(accessed on 3 October 2021)]. Available online: https://dk.upce.cz/bitstream/handle/10195/69422/HnilickovaI_Leidenska_mutace_LS_2017.pdf?sequence=1&isAllowed=y.

Vaše Laboratoře. [(accessed on 13 September 2021)]. Available online: https://www.vaselaboratore.cz/seznam-vysetreni/molekularni-biologie/item/faktor-ii-protrombin-g20210a.

Rosendaal F.R. Venous Thrombosis: A Multicausal Disease. Lancet. 1999;353:1167–1173. doi: 10.1016/S0140-6736(98)10266-0. PubMed DOI

Váchová B.T. Vliv Dlouhodobého Užívání Hormonální Antikoncepce Na Kvalitu Života Effect of Log-Term Use of Hormonal Contraceptives on Quality of Life. Pražská Vysoká škola Psychosociálních Studií; Praha, Czech Republic: 2018.

Penka M. Profylaxe Tromboembolické Nemoci. Geriatr. Gerontol. 2013;2:206–209.

Lerman C., Croyle R.T., Tercyak K.P., Hamann H. Genetic Testing: Psychological Aspects and Implications. J. Consult. Clin. Psychol. 2002;70:784–797. doi: 10.1037/0022-006X.70.3.784. PubMed DOI

Alberini A., Scasny M., Kohlová M.B., Melichar J. The Value of a Statistical Life in the Czech Republic: Evidence from a Contingent Valuation Study. [(accessed on 3 October 2021)]. Economics 2005. Available online: https://www.semanticscholar.org/paper/THE-VALUE-OF-A-STATISTICAL-LIFE-IN-THE-CZECH-FROM-A-Alberini-Mattei/bf863049fd6df68076fe44fd7cdc8485de0bb6a8#paper-header.

Dales R.E., Cakmak S., Vidal C.B. Air Pollution and Hospitalization for Venous Thromboembolic Disease in Chile. J. Thromb. Haemost. 2010;8:669–674. doi: 10.1111/j.1538-7836.2010.03760.x. PubMed DOI

Healthy Aging in Industrial Environment—HAIE Výzkum Vlivu Života v Průmyslovém Prostředí a Znečištění Ovzduší na Zdraví a Stárnutí Obyvatel. [(accessed on 10 September 2021)]. Available online: https://haie.osu.cz/en/main-page/

The Effectiveness of ddPCR for Detection of Point Mutations in Poor-Quality Saliva Samples

Frequency of Leiden Mutation in Newborns with Birth Weight below 1500 g